for prosthetic breast reconstruction include decreased time necessary to complete reconstruction; more consistent and natural appearing aesthetic results; decreased manipulation of the chest wall musculature. and improved soft-tissue support facilitating, in some cases, immediate, direct-to-implant reconstruction. [5] [6] [7] However, acellular dermal matrix use in breast reconstruction is not without disadvantages, with some prior studies demonstrating increased rates of seroma, inflammatory reactions, and infectious complications compared with total submuscular coverage. [8] [9] [10] Multiple different acellular dermal matrix products are now available, with varying data available to support their safety and efficacy. [11] [12] [13] [14] [15] [16] [17] The most commonly used and studied acellular dermal matrix, AlloDerm Regenerative Tissue Matrix (LifeCell Corp., Allergan, Dublin, Ireland) was originally available commercially as freeze-dried AlloDerm (freeze-dried acellular dermal matrix). 18 In 2010, AlloDerm sterile, ready-to-use acellular dermal matrix was introduced as an alternative option to the aseptic form, with the purported advantages being improved sterility and expedited intraoperative processing (2 minutes versus 30 minutes of rehydration for aseptic acellular dermal matrix). The U.S. Food and Drug Administration classifies AlloDerm as human tissue for transplantation. Both freeze-dried and ready-to-use acellular dermal matrix achieve a sterility assurance level of 10 -3 , but are differentiated by a terminal sterilization process set forth by the U.S. Food and Drug Administration that sterile ready-to-use acellular dermal matrix undergoes, but aseptic freeze-dried acellular dermal matrix does not. Although it is reasonable to expect ready-to-use acellular dermal matrix to have equivalent, if not favorable, clinical outcomes over aseptic freeze-dried acellular dermal matrix, there are limited data available to confirm this hypothesis. The few studies evaluating the safety and efficacy of AlloDerm ready-to-use report conflicting results regarding complications such as infection, explantation, and seroma. [19] [20] [21] [22] Unfortunately, these prior studies have been limited by small sample sizes, precluding the ability to adequately control for confounding variables. 18, 20 In fact, across all four prior studies on the topic, study populations ranged from 58 patients to 122 patients, resulting in a total population in the literature of only 364 patients. 19, [21] [22] [23] It is integral as technology evolves that new products undergo the same rigorous evaluation as their predecessors to ensure comparable safety and outcomes. Therefore, the purpose of this study was to compare clinical outcomes and complications, leveraging multivariable regression modeling to control for confounding variables, in women undergoing immediate implant-based breast reconstruction with ready-to-use and freeze-dried acellular dermal matrix. We hypothesize that ready-to-use acellular dermal matrix is associated with fewer infections and explantations than freeze-dried acellular dermal matrix.
PATIENTS AND METHODS
This study retrospectively analyzes a prospectively maintained database of all patients undergoing implant-based breast reconstruction at the Siteman Cancer Center in Saint Louis. With institutional review board approval (no. 201106126), all consecutive patients undergoing immediate postmastectomy implant-based breast reconstruction by three plastic surgeons (T.M.M., M.M.T., and K.E.B.) over an 11-year period, from January of 2005 to December of 2015, were identified. Mastectomy procedures were performed by a total of six breast surgeons. All patients had at least 2 years of follow-up, with patients receiving freezedried acellular dermal matrix undergoing immediate reconstruction from 2005 to 2010, and those receiving ready-to-use acellular dermal matrix undergoing reconstruction from 2010 to 2015. Inclusion criteria were patients older than 18 years, patients undergoing immediate breast reconstruction with a staged tissue-expander/implant approach or a direct-to-implant approach, and patients undergoing reconstruction with placement of either ready-to-use or freeze-dried acellular dermal matrix. Exclusion criteria included patients undergoing delayed implant-based breast reconstruction, without use of acellular dermal matrix, reconstructions performed by other plastic surgeons, acellular dermal matrix or mesh product other than ready-to-use or freeze-dried AlloDerm, prepectoral reconstructions, concomitant autologous flap, and patients with inadequate follow-up.
Prosthetic devices included in this study were anatomical or round and smooth or textured devices that were on consignment at our hospital. All tissue expanders used in tissue expander/ implant reconstructions were Allergan (Allergan, Inc., Dublin, Ireland) 133 MV devices. Implants used at the time of permanent implant exchange or in direct-to-implant reconstructions were either Allergan or Sientra (Sientra, Inc., Santa Barbara, Calif.) devices. Consistent techniques were used throughout the study period, with prosthetic devices placed in a partial submuscular plane following elevation of the pectoralis major muscle and acellular dermal matrix used for coverage of the lower pole as an inferolateral sling with either a nonperforated 8 × 16-cm sheet for tissue expander or a 10 × 20-cm sheet for directto-implant reconstruction. Two closed-suction drains, one superficial and one deep to the acellular dermal matrix, were placed on each side and removed when output was less than 30 cc over a 24-hour period. All patients received preoperative antibiotics according to the American Society of Plastic Surgeons Clinical Practice Guidelines and perioperative antibiotics until drain removal.
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Data and Statistical Analysis
Demographic and clinical data, including age, race, body mass index, patient comorbidities, smoking status, exposure to radiation therapy, exposure to adjuvant/neoadjuvant chemotherapy, use of endocrine therapy, cancer stage, laterality (unilateral versus bilateral) of reconstruction, indication for mastectomy (prophylactic or therapeutic), type of mastectomy (nipple-sparing, skin-sparing, or modified radical), and type of reconstruction (tissue expander/ implant versus direct-to-implant), were recorded. Postoperative clinical outcomes, including seroma, hematoma, surgical-site infection requiring intravenous antibiotics, explantation, wound dehiscence, mastectomy flap necrosis, and implant problems, were recorded. Implant problems were defined as implant exposure, malposition, deflation, or rupture. A particular patient may have had more than one outcome, as would be the case, for example, if an exposed implant was explanted because of a wound dehiscence. The primary clinical outcomes were surgical-site infection requiring intravenous antibiotics, prosthetic explantation, and presence of any surgical complication postoperatively. Explantation was defined as unplanned removal of the prosthetic device for any reason. Indications for unplanned explantation included infection, persistent seroma unresponsive to drainage interventions, device exposure, or pending exposure because of comprised soft-tissue coverage.
Statistical analyses were performed using SAS software (Version 9.4; SAS Institute, Inc., Cary, N.C.). An a priori power analysis to estimate appropriate sample size indicated 359 to 612 patients would be required per group assuming a baseline difference in primary outcome of 6 to 8 percent, with 80 percent power and a significance level of alpha = 0.05. Summary descriptive statistics were first tabulated. For continuous variables, mean and standard deviations are presented. For categorical variables, the number and proportion of study subjects in each level of categorical variable are presented. Chi-square analyses were used to compare categorical variables of interest. If the expected count of any subgroup was five or less, Fisher's exact test was used instead. For categorical variables with more than two subgroups, if the overall chi-square test indicated a statistically significant difference, individual chi-square tests were run against each subgroup to identify which specific subgroup was significantly different, with Bonferroni correction applied to the level of statistical significance to account for multiple testing. The t test was used to compare continuous variables of interest. Logistic regression modeling was used to quantify the effect of the type of acellular dermal matrix on the three primary outcomes while controlling for potential confounders. To be included in the multivariate analysis, potential confounders had to exhibit p < 0.010 on univariate logistic regression. Finals results are reported as adjusted odds ratios with confidence intervals. An alpha value of 0.05 indicated significance in all tests.
RESULTS
A total of 1285 patients who underwent 2039 immediate implant-based breast reconstructions after mastectomy were evaluated once inclusion and exclusion criteria were applied to an original cohort of 1846 patients. Patients were separated into two clinical cohorts: those undergoing breast reconstruction with aseptic freeze-dried acellular dermal matrix (612 patients; 910 breasts) and those undergoing breast reconstruction with sterile ready-to-use acellular dermal matrix (673 patients; 1129 breasts). Demographic and clinical characteristics between the two cohorts were compared ( Table 1 ). The groups were statistically similar (p > 0.05) with regard to age, body mass index, current tobacco use, diabetes, adjuvant radiation therapy, and endocrine therapy. Patients in the ready-to-use acellular dermal matrix group were significantly more likely to have prior chest wall irradiation (5.9 percent versus 0.7 percent; p < 0.0001), prophylactic mastectomy (7.3 percent versus 0.0 percent; p < 0.0001), and nipple-sparing mastectomy (21.4 percent versus 1.0 percent; p < 0.0001); undergo bilateral procedures (67.8 percent versus 48.7 percent; p < 0.0001); and have direct-to-implant reconstruction (9.4 percent versus 0.0 percent; p < 0.0001). Contrastingly, patients in the freeze-dried acellular dermal matrix group were significantly more likely to undergo neoadjuvant (29.9 percent versus 22.6 percent; p < 0.0001) and adjuvant (42.8 percent versus 28.9 percent; p < 0.0001) chemotherapy.
There were no statistically significant differences between the ready-to-use and freeze-dried acellular dermal matrix cohorts for the complications of surgical-site infection, wound dehiscence, mastectomy flap necrosis, implant problems, seroma, and hematoma (Table 2) . However, the freeze-dried acellular dermal matrix cohort had a significantly higher rate of explantation compared with the ready-to-use acellular dermal matrix cohort (18.0 percent versus 12.0 percent; p = 0.0036).
On univariate logistic regression, covariates significantly associated with the primary outcomes were identified and included in the multivariate logistic regression model. Adjusted odds ratios with 95 percent confidence intervals and p values are reported in Tables 3 through 5 for the impact of these covariates on the primary outcomes surgical-site infection, explantation, and complications. On multivariate logistic regression, body mass index was the only variable that independently predicted occurrence of surgical-site infection (OR, 1.039; 95 percent CI, 1.012 to 1.066; p = 0.0037). Patients having reconstruction with freeze-dried acellular dermal matrix did not have a significantly higher odds of experiencing surgicalsite infections compared to patients undergoing reconstruction with ready-to-use acellular dermal matrix (OR, 1.064; 95 percent CI, 0.732 to 1.546; 
DISCUSSION
Acellular dermal matrix use in implant-based breast reconstruction procedures has evolved considerably since initial reports. 2 Although multiple subsequent studies have evaluated the utility and safety of acellular dermal matrix use in immediate breast reconstruction, a majority of these focused on freeze-dried acellular dermal matrix. 18 As technology and the market for acellular dermal matrix expanded, novel products have been introduced into clinical practice and purported to have the same, or even an improved, safety profile as the original freeze-dried acellular dermal matrix. One such product is ready-to-use acellular dermal matrix. Although increasingly used clinically, to date, there has been minimal evidence to corroborate the comparative complication and safety profile of ready-to-use acellular dermal matrix versus the original freeze-dried acellular dermal matrix. Demonstrating the safety and efficacy of disparate operative techniques and technologies is critical to ensuring continued quality improvement in implant-based breast reconstruction. In this study, we demonstrated that immediate implantbased breast reconstruction with ready-to-use acellular dermal matrix resulted in a significantly lower rate of prosthetic explantation compared to reconstruction with freeze-dried acellular dermal matrix while maintaining a similar complication profile regarding overall complication rates, noninfectious wound healing complications, surgical-site infections, and seromas/hematomas. Of importance, we also demonstrated that use of freeze-dried acellular dermal matrix was an independent predictor of explantation complications in immediate implant-based breast reconstruction. Considered comprehensively, the results of our study confirm the overall safety and efficacy of ready-to-use acellular dermal matrix use as an adjunct to implant-based breast reconstruction procedures and suggest that ready-to-use acellular dermal matrix has clinical advantages over freezedried acellular dermal matrix, including accelerated rehydration time and significantly lower explantation rates.
This study of 1285 patients undergoing 2039 immediate implant-based breast reconstructions is the largest consecutive series in the literature to evaluate clinical outcomes for two disparate types of acellular dermal matrix. Our work builds on that of prior authors and expands the literature on the topic of sterile versus aseptic acellular dermal matrix use in implant-based breast reconstruction. In 2013, Weichman et al. reported their experience with aseptic freeze-dried acellular dermal matrix and sterile ready-to-use acellular dermal matrix in 345 consecutive patients, demonstrating a decreased rate of surgical-site infections and explantations in the ready-to-use cohort versus the freeze-dried cohort. 21 Similarly, Lewis et al. reported lower rates of infection and wound necrosis with ready-to-use versus freeze-dried acellular dermal matrix in a series of 105 patients in 2015. 23 However, contrastingly, Buseman et al. published a series of 34 patients who underwent reconstruction with ready-to-use or freeze-dried Plastic and Reconstructive Surgery • December 2018 acellular dermal matrix and showed a higher rate of seroma in the ready-to-use acellular dermal matrix group and no differences in infectious complications. 19 Similarly, in 2014, Yuen et al. also reported higher complication rates for seroma and cellulitis in ready-to-use acellular dermal matrix reconstructions compared to freeze-dried acellular dermal matrix reconstructions in a series of 103 patients. 22 Unfortunately, although providing valuable preliminary data on the topic, these studies were limited by small sample sizes that precluded adequately controlling for confounding clinical variables or identifying significant differences in clinical outcomes between study groups. Ultimately, the inconsistent results across these studies and methodologic limitations have made it difficult for clinicians to determine the relative value of ready-to-use acellular dermal matrix in comparison to freeze-dried acellular dermal matrix as an adjunct to immediate implant-based breast reconstruction procedures. 20 The strengths of our study are the large sample size, the ability to evaluate for independent predictors of the primary outcomes using multivariable logistic regression analyses, the ability to control for confounding variables in the analyses, and a 2-year minimum follow-up period to evaluate outcomes in all study patients.
There are several findings in this study that merit discussion. We did not find statistically significant differences in infectious complications between the ready-to-use and freeze-dried acellular dermal matrix cohorts (10.4 percent versus 11.3 percent; p = 0.6075). Also, aseptic acellular dermal matrix use was not an independent predictor of surgical-site infections in our series (OR, 1.064; 95 percent CI, 0.732 to 1.546; p = 0.746). One of the main reported advantages of ready-touse acellular dermal matrix is the terminal sterilization process that theoretically could reduce the rate of surgical-site infections compared with the aseptically processed freeze-dried acellular dermal matrix. In our study, this theoretical advantage was not substantiated by the data. Our overall rate of surgical-site infections is consistent with prior reports in the literature. [25] [26] [27] [28] Without question, eliminating this prosthesis as a source of bacterial contamination is critical and understandably is a focus of vendors who provide acellular dermal matrices. 11, 29 The breast, however, is not an innocent bystander, as it is contaminated with its own bacterial microbiome 30 that is more diverse than the skin, 31 and can vary based on patient demographics, 32 and a breast cancer diagnosis. 31, 33 Explantation rates were relatively high in our study, and were predicted by freeze-dried versus ready-to-use acellular dermal matrix use, smoking, and body mass index. We included all prosthetic explantations (tissue expander or implant) in our data and captured outcomes out to a minimum of 2 years after initial reconstruction. When accounting for this length of follow-up, our complication rates are similar to recent studies in the literature. 28, 34 In recent studies published from the Mastectomy Reconstruction Outcomes Consortium with 2-year outcomes data, the rate of major complications requiring rehospitalization and/or reoperation were 22.4 percent in patients undergoing implant-based reconstruction with acellular dermal matrix, and the rates of reconstructive failure ranged from 3.7 to 18.7 percent. 28, 34 Furthermore, in our series, 20.3 percent of women in the freeze-dried acellular dermal matrix and 15.2 percent in the ready-to-use acellular dermal matrix groups were current smokers (Table 1) , dramatically higher than the 2.4 percent incidence of smokers in the series reported by Srinivasa et al. 35 and 5.7 to 6.7 percent by Weichman et al. 21 According to the most recent report from the Centers for Disease Control and Prevention, our data are consistent with the general population where, in 2015, greater than or equal to 17 percent of women aged 25 to 65 years, and particularly those in the Midwest, smoked. 36 In addition, mean body mass index in our series was 28.3 ± 5.1 kg/m 2 , significantly higher than that reported in other large series evaluating immediate prosthetic breast reconstruction. 21, 35, 37 Again, our data may be more reflective of the general population, as the most recent comprehensive national report on obesity indicates that 30 to 35 percent of white women and more than 35 percent of African American women have a body mass index greater than 30 kg/m 2 . 38 Although we have traditionally made every attempt to offer immediate breast reconstruction to patients following mastectomy, treating this population differently than those seeking elective cosmetic surgery, we acknowledge that this has a potentially higher risk for complications. To limit this for high-risk patients, we now more strongly promote delayed reconstruction to limit complication rates. 26, 37, 39, 40 Compared to ready-to-use acellular dermal matrix, our data suggest an association between freeze-dried acellular dermal matrix and significantly higher rates of explantation in the absence of concomitant increases in other complications typically associated with higher explantation rates such as surgical-site infection, wound dehiscence, or mastectomy flap necrosis. This discrepancy may be attributable to several factors. Wound dehiscence and mastectomy flap necrosis rates, both of which can lead to overt or imminent device exposure, were noticeably higher in the freezedried acellular dermal matrix group (Table 2) but did not, independently, achieve statistical significance. Although our analysis controlled for other potential confounding differences between the freeze-dried and ready-to-use acellular dermal matrix cohorts such as cancer stage, body mass index, and smoking (Table 1) , we did not control for factors such as flap thickness, surgical oncologist, initial fill volumes, and the impact of clinical experience with tissue expander reconstruction supplemented with an acellular dermal matrix sling. The ready-to-use acellular dermal matrix group may have benefited from changes in surgical approach that were derived from operator experience, including initial fill volumes, ability to judge skin perfusion clinically with or without adjunctive imaging technology, and behaviors including the tendency to watch versus explant a tissue expander from an infected versus potentially only inflamed red breast. Later in the series, ready-to-use acellular dermal matrix may have been used in nipple-sparing mastectomy and direct-to-implant reconstructions. Thus, whereas on the one hand, the ready-to-use acellular dermal matrix patients may have benefited from our extensive experience with freeze-dried acellular dermal matrix, skin-sparing mastectomies, and tissue-expander reconstruction, on the other hand, they were susceptible to the learning curve associated with nipple-sparing mastectomy and directto-implant reconstructions. In this retrospective study design, we cannot rule out an element of selection bias. Patients deemed unfavorable candidates for prosthetic reconstruction from either cohort would be more likely to undergo autologous flap reconstruction or conversion to a delayed reconstruction. In terms of when to operate, and which operation to perform, patients in the ready-to-use acellular dermal matrix group may have benefited from judgment informed by a greater experience than that afforded the freezedried acellular dermal matrix group.
The results of this study have several implications for clinical practice. For immediate implantbased breast reconstruction with an acellular dermal matrix, a shorter rehydration time coupled with our findings of an equivalent if not favorable complication profile regarding explantation rates support the use of ready-to-use acellular dermal matrix. This is important because, until recently, some insurance companies considered ready-touse acellular dermal matrix to be experimental, arguing that there was insufficient data to support its use, and would not reimburse hospitals for its use in breast reconstruction. In addition to clinicians and patients, these data are also relevant to hospital administrators and payer groups. As the U.S. health care system shifts to value-based health care (minimizing cost while maximizing outcomes) and hospitals attempt to control supply costs in operations, it is important to have comparative studies for devices and products frequently used in routine procedures. In addition to AlloDerm ready-to-use acellular dermal matrix, there are several new acellular dermal matrix products now on the market for clinicians to use in implantbased breast reconstruction procedures. Evaluating these products with similar rigor to the more established acellular dermal matrix products is critical to ensure patient safety and maintain an evidence-based clinical practice. In addition to comparing two different types of acellular dermal matrix, this study also provides valuable data on risk factors for complications in immediate implant-based breast reconstruction with acellular dermal matrix, and identifies patients who may benefit from delayed reconstruction 25, 26, 37 or autologous reconstruction. 41 We gave oral antibiotics while drains were in, but this approach is not supported by the Surgical Care Improvement Project, which recommends stopping antibiotics within 24 hours of surgery. 42 These guidelines, however, assume that the breast is a clean surgical site, but it is not. [30] [31] [32] 43 A precision, evidence-based approach that tailors the type and duration of antibiotic use to a patient's genome and microbiome represents the next step for limiting infections in tissue expander patients. 44, 45 Ultimately, breast reconstruction remains a preference-sensitive decision with a shared decision-making approach that, when optimized, considers patients' values and preferences and balances those against risks for adverse outcomes associated with different techniques. 46 The primary limitation of this study is the retrospective, nonrandomized study design. Ideally, a study with level I evidence could be performed to compare freeze-dried and ready-to-use acellular dermal matrix; however, conducting a randomized controlled trial with sufficient power to detect clinically meaningful differences in outcomes across the two groups is resource intensive and was not practical for this study. We acknowledge with a retrospective study design the presence of unknown confounders that may impact our results.
